Krsnaa Diagnostics Limited (KRSNAA)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- H1 FY27 revenue crossed INR 507 Cr, +27% y-y; Q2 revenue INR 271 Cr, +32% y-y
- EBITDA margin at 27% in Q2, slight moderation due to Rajasthan project ramp-up
- Rajasthan project ramp-up ongoing; expected INR 250 Cr annualized revenue next year
- Receivables at INR 470 Cr; INR 200 Cr expected collection in Q3
- Cash-based revenues targeted at 40-45% of total by FY27, improving cash flow
- Retail revenue INR 23.5 Cr in Q2, +35% y-y; retail to reach double-digit % of revenue in 2-3 years
- Focus on utilization, operational efficiency, and ROCE improvement to high teens
- New PPP projects in PET-CT and CT scans to drive growth
- Retail business operational breakeven expected by Q3-Q4 FY27
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 KRSNAA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add KRSNAA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Krsnaa Diagnostics Limited
Important.
The summary above is generated automatically from Krsnaa Diagnostics Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.